Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
The Medicines Co.'s New Minocin Formulation Approved
Article By:
Zacks Investment Research
Monday, April 20, 2015 5:56 PM EDT
The Medicines Company gained FDA approval for its supplemental new drug application for a new formulation of Minocin. However, there are other stocks within the health care sector which are more deserving of investors attention.
U.S. Stocks Switched Between Small Gains And Losses
Article By:
BioMedReports
Friday, November 7, 2014 4:36 PM EDT
With the main benchmarks hovering near record levels in the wake of a solid jobs report, a key payrolls data showed the economy added 214,000 jobs in October, while the unemployment rate ticked down to 5.8% — a broadly positive reading.
Regeneron And Sanofi Reported Positive Top-Line Results Of Alirocumab For Hypercholesterolemia Treatment
Article By:
Dr. Hung Tran
Wednesday, July 30, 2014 3:36 PM EDT
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)’s shares soared as much as $20.62, hitting $325.13, or 6.77 percent as the company received one good news after the next.
Regeneron Pharmaceuticals' Shares Predicted To Rise Tomorrow With FDA Approval Of EYLEA
Article By:
Dr. Hung Tran
Wednesday, July 30, 2014 8:27 AM EDT
Regeneron’s shares are predicted to rise tomorrow as the company received the FDA approval of EYLEA (aflibercept) injection for the treatment of diabetic macular edema (DME) – a common complication in the eyes of diabetic patients.